Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme

References

• World Health Organization. Cancer [Internet]. Geneva (Switzerland): WHO; 2021 [cited 2022 Feb 3]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Norman A. On the origin of cancer foci. Cancer. 1952;5(3):581–582.
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339–348.
   PubMed Web of Science ®Google Scholar
• Nitiss JL, Kiianitsa K, Sun Y, Nitiss KC, Maizels N. Topoisomerase assays. Curr Protoc. 2021;1(10):e250.
   PubMedGoogle Scholar
• Lee JH, Berger JM. Cell cycle-dependent control and roles of DNA topoisomerase II. Genes. 2019;10(11):859.
   Google Scholar
• Baguley BC, Drummond CJ, Chen YY, Finlay GJ. DNA-binding anticancer drugs: one target, two actions. Molecules. 2021;26(3):552.
   Google Scholar
• Sissi C, Palumbo M. Effects of magnesium and related divalent metal ions in topoisomerase structure and function. Nucleic Acids Res. 2009;37(3):702–711.
   PubMed Web of Science ®Google Scholar
• Lehninger A, Nelson DL, Cox MM. Biochemistry principles. 7th ed. New York: W.H. Freeman; 2017. p. 1328.
   Google Scholar
• Delgado JL, Hsieh C-M, Chan N-L, Hiasa H. Topoisomerases as anticancer targets. Biochem J. 2018;475(2):373–398.
   PubMedGoogle Scholar
• Hevener KE, Verstak TA, Lutat KE, Riggsbee DL, Mooney JW. Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B. 2018;8(6):844–861.
   PubMed Web of Science ®Google Scholar
• Buzun K, Bielawska A, Bielawski K, Gornowicz A. DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem. 2020;35(1):1781–1799.
   PubMed Web of Science ®Google Scholar
• Skok Z, Zidar N, Kikelj D, Ilas J. Dual inhibitors of human DNA topoisomerase II and other cancer- related targets. J Med Chem. 2020;63(3):884–904.
   PubMed Web of Science ®Google Scholar
• Johnson-Arbor K, Dubey R. Doxorubicin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 29083582.
   Google Scholar
• Abdel-Aal MAA, Abdel-Aziz SA, Shaykoon MSA, Abuo-Rahma GEDA. Towards anticancer fluoroquinolones: a review article. Arch Pharm. 2019;352(7):e1800376.
   PubMed Web of Science ®Google Scholar
• Ezelarab HAA, Abbas SH, Hassan HA, Abuo-Rahma GEDA. Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm Chem Life Sci. 2018;351(9):1800141.
   PubMed Web of Science ®Google Scholar
• Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934–946.
   PubMed Web of Science ®Google Scholar
• Kathiravan MK, Khilare MM, Nikoomanesh K, Aparna S, Jain KS. Topoisomerase as target for antibacterial and anticancer drug discovery. J Enzyme Inhib Med Chem. 2013;28(3):419–435.
   PubMed Web of Science ®Google Scholar
• Idowu T, Schweizer F. Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics. 2017;6(4):26.
   Google Scholar
• Gouvea LR, Garcia LS, Lachter DR, Nunes PR, de Castro Pereira F, Silveira-Lacerda EP, Louro SRW, Barbeira PJS, Teixeira LR. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action. Eur J Med Chem. 2012;55:67–73.
   PubMed Web of Science ®Google Scholar
• Samir M, Ramadan M, Hamed M, Osman M, Abou-Rahma G. Recent strategies in design of antitumor and antibacterial fluoroquinolones. J Adv Biomed Pharm Sci. 2021;4(3):134–151.
   Google Scholar
• Bisacchi GS, Hale MR. A “double-edged” scaffold: antitumor power within the antibacterial quinolone. Curr Med Chem. 2016;23(6):520–577.
   Google Scholar
• Wang L-L, Battini N, Rammohan RY, Bheemanaboina S-L, Zhang CHZ. Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation. Eur J Med Chem. 2019;167:105–123.
   PubMed Web of Science ®Google Scholar
• Kloskowski T, Szeliski K, Fekner Z, Rasmus M, Paweł D, Wolska A. Ciprofloxacin and levofloxacin as potential drugs in genitourinary cancer treatment – the effect of dose-response on 2d and 3d cell cultures. Int J Mol Sci. 2021;22(21):11970.
   Google Scholar
• Gupta P, Gao HL, Ashar YV, Karadkhelkar NM, Yoganathan S, Chen ZS. Ciprofloxacin enhances the chemosensitivity of cancer cells to ABCB1 substrates. Int J Mol Sci. 2019;20(2):268.
   PubMed Web of Science ®Google Scholar
• Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002;86(3):443–448.
   PubMed Web of Science ®Google Scholar
• Yadav V, Varshney P, Sultana S, Yadav J, Saini N. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer. 2015;15(1):1–15.
   PubMedGoogle Scholar
• Liu H, Huang J, Wang J, Wang M, Liu M, Wang B, Guo H, Lu Y. Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety. Eur J Med Chem. 2014;86:628–638.
   PubMed Web of Science ®Google Scholar
• Mohammadhosseini N, Alipanahi Z, Alipour E, Emami S, Faramarzi MA, Samadi N, Khoshnevis N, Shafiee A, Foroumadi A. Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety. DARU. 2012;20(1):1.
   PubMedGoogle Scholar
• Gao F, Zhang X, Wang T, Xiao J. Quinolone hybrids and their anti-cancer activities: an overview. Eur J Med Chem. 2019;165:59–79.
   PubMed Web of Science ®Google Scholar
• Zhang GF, Zhang S, Pan B, Liu X, Feng LS. 4-Quinolone derivatives and their activities against Gram positive pathogens. Eur J Med Chem. 2018;143:710–723.
   PubMed Web of Science ®Google Scholar
• Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anticancer Agents. 2003;3(6):439–450.
   PubMedGoogle Scholar
• Suaifan GARY, Mohammed AAM. Fluoroquinolones structural and medicinal developments (2013–2018): where are we now? Bioorg Med Chem. 2019;27(14):3005–3060.
   PubMed Web of Science ®Google Scholar
• Liu J, Ren Z, Fan L, Wei J, Tang X, Xu X, Yang D. Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents. Bioorg Med Chem. 2019;27(1):175–187.
   PubMed Web of Science ®Google Scholar
• Feng L, Lv K, Liu M, Wang S, Zhao J, You X, Li S, Cao J, Guo H. Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety. Eur J Med Chem. 2012;55:125–136.
   PubMed Web of Science ®Google Scholar
• Zhang YB, Feng LS, You XF, Guo Q, Guo HY, Liu ML. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-methyl-4-methylaminopiperidin-1-yl)-fluoroquinolone derivatives. Arch Pharm. 2010;343(3):143–151.
   PubMed Web of Science ®Google Scholar
• Abuo-Rahma GDAA, Sarhan HA, Gad GFM. Design, synthesis, antibacterial activity and physicochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin. Bioorg Med Chem. 2009;17(11):3879–3886.
   PubMed Web of Science ®Google Scholar
• Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother. 2000;44(2):320–325.
   PubMed Web of Science ®Google Scholar
• Kassab AE, Gedawy EM. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity. Eur J Med Chem. 2018;150:403–418.
   PubMed Web of Science ®Google Scholar
• Khélifa T, Beck WT. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol. 1999;55(3):548–556.
   PubMed Web of Science ®Google Scholar
• Hotinski AK, Lewis ID, Ross DM. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother. 2015;16(9):1395–1402.
   PubMed Web of Science ®Google Scholar
• Kohlbrenner WE, Wideburg N, Weigl D, Saldivar A, Chu DTW. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob Agents Chemother. 1992;36(1):81–86.
   PubMed Web of Science ®Google Scholar
• Chauhan S, Paliwal S, Chauhan R. Anticancer activity of pyrazole via different biological mechanisms. Synth Commun. 2014;44(10):1333–1374.
   Web of Science ®Google Scholar
• Luzina EL, Popov AV. Synthesis and anticancer activity evaluation of 3,4-mono- and bicyclosubstituted N-(het)aryl trifluoromethyl succinimides. J Fluor Chem. 2014;168:121–127.
   PubMed Web of Science ®Google Scholar
• Milosevic NP, Kojic V, Curcic J, Jakimov D, Milic N, Banjac N, Uscumlic G, Kaliszan R. Evaluation of in silico pharmacokinetic properties and in vitro cytotoxic activity of selected newly synthesized N-succinimide derivatives. J Pharm Biomed Anal. 2017;137:252–257.
   PubMed Web of Science ®Google Scholar
• Tan A, Yaglioglu AS, Kishali NH, Sahin E, Kara Y. Evaluation of cytotoxic potentials of some isoindole-1,3-dione derivatives on HeLa, C6 and A549 cancer cell lines. Med Chem. 2020;16(1):69–77.
   PubMed Web of Science ®Google Scholar
• Firoozpour L, Gao L, Moghimi S, Pasalar P, Davoodi J, Wang M-W, Rezaei Z, Dadgar A, Yahyavi H, Amanlou M, et al. Efficient synthesis, biological evaluation, and docking study of isatin based derivatives as caspase inhibitors. J Enzyme Inhib Med Chem. 2020;35(1):1674–1684.
   PubMed Web of Science ®Google Scholar
• Ma L, Wang H, Wang J, Liu L, Zhang S, Bu M. Novel steroidal 5α,8α-endoperoxide derivatives with semicarbazone/thiosemicarbazone side-chain as apoptotic inducers through an intrinsic apoptosis pathway: design, synthesis and biological studies. Molecules. 2020;25(5):1209.
   PubMed Web of Science ®Google Scholar
• Muğlu H. Synthesis, characterization, and antioxidant activity of some new N4-aryl substituted-5-methoxyisatin-β-thiosemicarbazone derivatives. Res Chem Intermed. 2020;46(4):2083–2098.
   Web of Science ®Google Scholar
• El Majzoub R, Fayyad-Kazan M, Nasr El Dine A, Makki R, Hamade E, Grée R, Hachem A, Talhouk R, Fayyad-Kazan H, Badran B, et al. A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA-125a-5p and miRNA-181a-5p. Genes Genomics. 2019;41(12):1431–1443.
   PubMed Web of Science ®Google Scholar
• Hsu DC, Roth HS, West DC, Botham RC, Novotny CJ, Schmid SC, Hergenrother PJ. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1). ACS Comb Sci. 2012;14(1):44–50.
   PubMed Web of Science ®Google Scholar
• Liang Z, Zhang D, Ai J, Chen L, Wang H, Kong X, Zheng M, Liu H, Luo C, Geng M, et al. Identification and synthesis of N′-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase. Bioorg Med Chem Lett. 2011;21(12):3749–3754.
   PubMed Web of Science ®Google Scholar
• Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted αIIbβ3:PAC-1 molecular recognition. Biochemistry. 2009;48(35):8355–8365.
   PubMed Web of Science ®Google Scholar
• Kasiotis KM, Tzanetou EN, Haroutounian SA. Pyrazoles as potential anti-angiogenesis agents: a contemporary overview. Front Chem. 2014;2:78–77.
   PubMed Web of Science ®Google Scholar
• Awadallah FM, Piazza GA, Gary BD, Keeton AB, Canzoneri JC. Synthesis of some dihydropyrimidine-based compounds bearing pyrazoline moiety and evaluation of their antiproliferative activity. Eur J Med Chem. 2013;70:273–279.
   PubMed Web of Science ®Google Scholar
• Rathore P, Yaseen S, Ovais S, Bashir R, Yaseen R, Hameed AD, Samim M, Gupta R, Hussain F, Javed K, et al. Synthesis and evaluation of some new pyrazoline substituted benzenesulfonylureas as potential antiproliferative agents. Bioorg Med Chem Lett. 2014;24(7):1685–1691.
   PubMed Web of Science ®Google Scholar
• George RF, Fouad MA, Gomaa IEO. Synthesis and cytotoxic activities of some pyrazoline derivatives bearing phenyl pyridazine core as new apoptosis inducers. Eur J Med Chem. 2016;112:48–59.
   PubMed Web of Science ®Google Scholar
• Fahmy HH, Khalifa NM, Ismail MMF, El-Sahrawy HM, Nossier ES. Biological validation of novel polysubstituted pyrazole candidates with in vitro anticancer activities. Molecules. 2016;21(3):271.
   PubMed Web of Science ®Google Scholar
• Best J, Schotten C, Lohmann G, Gerken G, Dechêne A. Tivantinib for the treatment of hepatocellular carcinoma. Expert Opin Pharmacother. 2017;18(7):727–733.
   PubMed Web of Science ®Google Scholar
• Devi KS, Subramani P, Parthiban S, Sundaraganesan N. One-pot synthesis, spectroscopic characterizations, quantum chemical calculations, docking and cytotoxicity of 1-((dibenzylamino)methyl)pyrrolidine-2,5-dione. J Mol Struct. 2020;1203:127403.
   Web of Science ®Google Scholar
• Han SH, Kim S, De U, Mishra NK, Park J, Sharma S, Kwak JH, Han S, Kim HS, Kim IS, et al. Synthesis of succinimide-containing chromones, naphthoquinones, and xanthones under Rh(III) catalysis: evaluation of anticancer activity. J Org Chem. 2016;81(24):12416–12425.
   PubMed Web of Science ®Google Scholar
• Mitra I, Mukherjee S, Reddy BVP, Dasgupta S, Bose KJC, Mukherjee S, Linert W, Moi SC. Benzimidazole based Pt(II) complexes with better normal cell viability than cisplatin: synthesis, substitution behavior, cytotoxicity, DNA binding and DFT study. RSC Adv. 2016;6(80):76600–76613.
   Web of Science ®Google Scholar
• Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012;424(3–4):109–124.
   PubMed Web of Science ®Google Scholar
• Protein Data Bank. Available from: http://www.rcsb.org/pdb.
   Google Scholar
• Vincenzi B, Frezza AM, Santini D, Tonini G. New therapies in soft tissue sarcoma. Expert Opin Emerg Drugs. 2010;15(2):237–248.
   PubMed Web of Science ®Google Scholar
• Poli A, Mongiorgi S, Cocco L, Follo MY. Protein kinase C involvement in cell cycle modulation. Biochem Soc Trans. 2014;42(5):1471–1476.
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, Lau LF, Raychaudhuri P. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem. 2009;284(44):30695–30707.
   PubMed Web of Science ®Google Scholar
• Black AR, Black JD. Protein kinase C signaling and cell cycle regulation. Front Immunol. 2012;3:423.
   PubMed Web of Science ®Google Scholar
• Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21(6):1960.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman IM, Mustafa M, Mohamed SA, Yahia R, Abdel-Aziz M, Abuo-Rahma GE-DA, Hayallah AM. Novel Mannich bases of ciprofloxacin with improved physicochemical properties, antibacterial, anticancer activities and caspase-3 mediated apoptosis. Bioorg Chem. 2021;107:104629.
   PubMed Web of Science ®Google Scholar
• D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–592.
   PubMed Web of Science ®Google Scholar
• Obeng E. Apoptosis (programmed cell death) and its signals - a review. Braz J Biol. 2021;81(4):1133–1143.
   PubMedGoogle Scholar
• Majtnerová P, Roušar T. An overview of apoptosis assays detecting DNA fragmentation. Mol Biol Rep. 2018;45(5):1469–1478.
   PubMed Web of Science ®Google Scholar
• Araya LE, Soni IV, Hardy JA, Julien O. Deorphanizing caspase-3 and caspase-9 substrates in and out of apoptosis with deep substrate profiling. ACS Chem Biol. 2021;16(11):2280–2296.
   PubMed Web of Science ®Google Scholar
• Mai F-Y, He P, Ye J-Z, Xu L-H, Ouyang D-Y, Li C-G, Zeng Q-Z, Zeng C-Y, Zhang C-C, He X-H, et al. Caspase-3-mediated GSDME activation contributes to cisplatin- and doxorubicin-induced secondary necrosis in mouse macrophages. Cell Prolif. 2019;52(5):e12663.
   PubMed Web of Science ®Google Scholar
• Jeelani R, Chatzicharalampous C, Kohan-Ghadr H-R, Bai D, Morris RT, Sliskovic I, Awonuga A, Abu-Soud HM. Hypochlorous acid reversibly inhibits caspase-3: a potential regulator of apoptosis. Free Radic Res. 2020;54(1):43–56.
   PubMed Web of Science ®Google Scholar
• Beroske L, Van den Wyngaert T, Stroobants S, Van der Veken P, Elvas F. Molecular imaging of apoptosis: the case of caspase-3 radiotracers. Int J Mol Sci. 2021;22(8):3948.
   PubMed Web of Science ®Google Scholar
• Baviskar AT, Amrutkar SM, Trivedi N, Chaudhary V, Nayak A, Guchhait SK, Banerjee UC, Bharatam PV, Kundu CN. Switch in site of inhibition: a strategy for structure-based discovery of human topoisomerase IIα catalytic inhibitors. ACS Med Chem Lett. 2015;6(4):481–485.
   PubMed Web of Science ®Google Scholar